Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Trial Profile

Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs MSB 0011359C (Primary) ; Temozolomide (Primary) ; Topotecan (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2019 Planned number of patients changed from 53 to 57.
    • 07 Sep 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 5 Sep 2018 to 12 Sep 2018.
    • 28 Aug 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Aug 2018 to 3 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top